81 191

Cited 0 times in

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL).

Authors
 Yu Ri Kim  ;  Jin Seok Kim  ;  Yoo Hong Min  ;  Dok Hyun Yoon  ;  Ho-Jin Shin  ;  Yeung-Chul Mun  ;  Yong Park  ;  Young Rok Do  ;  Seong Hyun Jeong  ;  Joon Seong Park  ;  Sung Yong Oh  ;  Suee Lee  ;  Eun Kyung Park  ;  Joung-Soon Jang  ;  Won-Sik Lee  ;  Hwe-Won Lee  ;  HyeonSeok Eom  ;  Jae-sook Ahn  ;  Jae-Heon Jeong  ;  Sun Kyung Baek  ;  Seok Jin Kim  ;  Won Seog Kim  ;  Cheolwon Suh 
Citation
 JOURNAL OF HEMATOLOGY & ONCOLOGY, Vol.5 : 49, 2012 
Journal Title
 JOURNAL OF HEMATOLOGY & ONCOLOGY 
Issue Date
2012
MeSH
Adult ; Aged ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Cohort Studies ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy* ; Lymphoma, Large B-Cell, Diffuse/mortality ; Lymphoma, Large B-Cell, Diffuse/pathology ; Middle Aged ; Prednisone/administration & dosage ; Prognosis ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Vincristine/administration & dosage
Keywords
Primary adrenal lymphoma ; Diffuse large B-cell lymphoma ; Prognostic factor ; R-CHOP
Abstract
BACKGROUND: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. METHODS: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. RESULTS: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). CONCLUSIONS: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.
Files in This Item:
T201202989.pdf Download
DOI
22889180
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Yu Ri(김유리) ORCID logo https://orcid.org/0000-0001-5505-0142
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/90844
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse